Ga onbeperkt met Magzter GOLD
Krijg onbeperkte toegang tot meer dan 9000 tijdschriften, kranten en Premium-verhalen voor slechts
Poging GOUD - Vrij
IP gets recognition as book of standards in 17 countries
Chronicle Pharmabiz
|November 20, 2025
THE Indian Pharmacopoeia (IP) as a book of standards for medicines has been recognized by 17 countries till date. This will ensure quality medicines being manufactured and/or imported in the respective foreign countries and hence boost exports.
The Indian Pharmacopoeia Commission (IPC) signed its first IP recognition Memorandum of Understanding (MoU) with Afghanistan in 2019, making it the first country to officially recognize the Indian Pharmacopoeia.
In order to ensure the quality of medicinal products, the legal and scientific standards of Indian Pharmacopoeia are authoritative in nature and are enforced by the regulatory authorities for quality control of medicines in India.
This recognition of Indian Pharmacopoeia in the respective foreign countries would remove double regulation, duplication in testing and post importation checks to boost the India pharma exports to these countries. Indian drug exporters would thus, gain a competitive edge and trade would become more remunerative.
Dit verhaal komt uit de November 20, 2025-editie van Chronicle Pharmabiz.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Chronicle Pharmabiz
Chronicle Pharmabiz
'Indian pharma's fundamentals signal shift towards science-driven models'
THE Indian pharmaceutical industry's defining trend currently is the shift from volume-led growth to valueand innovation-led expansion.
1 mins
November 20, 2025
Chronicle Pharmabiz
Rejection of trial waiver for Hetero's lenacapavir will impact India, LMICS: TWN
THE decision of the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) to reject Hetero Lab's request for waiver of two studies for the manufacturing and marketing of generic lenacapavir 300 mg tablet will impact the accessibility of the generic equivalent of Gilead's HIV drug in India and the low-and-middle income countries (LMICs), according to an independent nonprofit international research and advocacy organisation.
3 mins
November 20, 2025
Chronicle Pharmabiz
APPC election hit by allegations
As preparations for the Andhra Pradesh Pharmacy Council (APPC) elections 2025 are underway, various panels are busy finalizing their candidates, setting the stage for a charged contest over the future governance of the state's pharmacy profession.
1 mins
November 20, 2025
Chronicle Pharmabiz
ICMR lists important pathogens causing critical infections
THE Division of Communicable Diseases of Indian Council of Medical Research (ICMR) has listed important pathogens causing critical infectious syndromes in India to guide patient management, public health policies, and biomedical research and development (R&D).
2 mins
November 20, 2025
Chronicle Pharmabiz
ICMR invites EoIs for data contribution for pregnancy cohort studies
IN order to understand hypothyroidism during pregnancy among Indian women, the Indian Council of Medical Research (ICMR) has invited Expression of Interests (Eols) from researchers and institutions to contribute data from ongoing or completed pregnancy cohort studies or randomized controlled trials (RCTs).
2 mins
November 20, 2025
Chronicle Pharmabiz
Alembic gets US FDA final approval for diltiazem tablets.
ALEMBIC Pharmaceuticals A Limited (Alembic), a verti cally integrated research and development pharmaceutical company, announced that it has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) diltiazem hydrochloride tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg.
1 min
November 20, 2025
Chronicle Pharmabiz
A Scheme to Unleash Innovation Potential
THE Department of Pharmaceuticals (DoP) has recently notified the amendments to the Rs. 5,000 crore Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme which will build an advanced R&D infrastructure across the country.
2 mins
November 20, 2025
Chronicle Pharmabiz
Alkem Lab reports 17% revenue growth in Q2 FY26
ALKEM Laboratories Ltd. to report and consolidated financial results for the second quarter ended September 30, 2025. The board of directors took record of these results at its meeting held in Mumbai today.
1 mins
November 20, 2025
Chronicle Pharmabiz
IP gets recognition as book of standards in 17 countries
THE Indian Pharmacopoeia (IP) as a book of standards for medicines has been recognized by 17 countries till date. This will ensure quality medicines being manufactured and/or imported in the respective foreign countries and hence boost exports.
2 mins
November 20, 2025
Chronicle Pharmabiz
Ghaziabad-based IPC inks MoU with TNPC
THE Ghaziabad-based Indian Pharmacopoeia Commission (IPC) has signed a Memorandum of Understanding (MoU) with the Tamil Nadu Pharmacy Council (TNPC) to promote safe and rational use of medicines through joint initiatives in pharmacovigilance, patient safety, and professional awareness among pharmacists.
1 mins
November 20, 2025
Listen
Translate
Change font size